^
    Back
    Association details:
    Biomarker:RET rearrangement
    Cancer:Non Small Cell Lung Cancer
    Drug:Retevmo (selpercatinib) (RET inhibitor)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: A2 - Guideline
    New
    Source:
    ASCO.org
    Title:

    Therapy for Stage IV Non–Small-Cell Lung Cancer With Driver Alterations: ASCO Living Guideline

    Published date:
    07/11/2022
    Excerpt:
    For patients with a RET rearrangement, a PS of 0-2, and previously untreated NSCLC, clinicians may offer selpercatinib or pralsetinib. In second line, for patients with a RET rearrangement who have not received RET-targeted therapy, clinicians may offer selpercatinib or pralsetinib.
    DOI:
    10.1200/JCO.22.00824
    Evidence Level:
    Sensitive: A2 - Guideline
    Source:
    NCCN
    Published date:
    09/15/2020
    Excerpt:
    The Panel recommends selpercatinib, pralsetinib, cabozantinib, or vandetanib (category 2B for vandetanib) as subsequent therapy options for select patients with RET rearrangement positive metastatic NSCLC who have not previously received these agents…